APLT AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a low value rating. If your investment strategy is value-oriented and you have long-term positions, it's crucial to adhere to your exit plan and consider reducing holdings.
APLT Current Performance
0.38%
Applied therapeutics inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to APLT
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
ENGN | Engene holdings inc | - | 1 | 4 | - | 1 | |
TVGN | Tevogen bio holdings inc | - | 2 | 4 | - | 1 | |
SGMO | Sangamo therapeutics inc | 3 | 3 | 2 | 1 | 1 | |
MURA | Mural oncology plc | - | 3 | 2 | - | 1 | |
OCGN | Ocugen inc | 2 | 3 | 3 | 1 | 1 |
- ENGN Engene holdings incValue -Trend 1Swing Trading 4Whale Interest -Dividend 1See more
APLT Profile
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company's lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.